Nirav Shah (@niravshahmd)

X
CAR-T sequencing and emerging cell therapy platforms: how will you decide? Join me, Drs. Ahmed (@drsairahahmed) and Nasta on Fri 12/11 at 7:00 PM CST, for a @PeerView and @HealthTree symposium during #ASH26: bit.ly/2026-CART-T

www.peerview.com Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging... See the latest #NHL live event from @PeerView #ASH26 #MedEd

Nirav Shah @niravshahmd Apr 22, 2025

ascopost.com/news/april-202…

ascopost.com Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 CAR T Cells in Relapsed/Refractory Mantle Cell... In a single-center phase I/II study reported in the Journal of Clinical Oncology, Shah et al evaluated whether adaptive manufactured lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T-cell treatment was...

Nirav Shah @niravshahmd Mar 31, 2025

Excited to share a publication years in the making, our experience with CAR20.19 T cells in relapsed, refractory Mantle Cell Lymphoma now a. Excellent outcomes from IIT @MCWCancerCenter Thanks to great collaborators @timfenske @MediHumdani and many more!

ascopubs.org/doi/10.1200/JC…

ascopubs.org Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor... PURPOSEMantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by t(11;14) and bright CD20 expression. To improve outcomes from single targeted CD19 chimeric antigen receptor...

Nirav Shah @niravshahmd Nov 21, 2024

ash.confex.com/ash/2024/webpr…

Excited to share CAR20.19 multicenter data--a nearly 10 year effort. Developed a Phase 1 trial with this construct in 2016, first patient treated at MCW in 2017. Published Phase 1 with target dose, fresh-in/fresh-out CAR cells in Nature Med in 2020.

Nirav Shah @niravshahmd Nov 29, 2023

There is no worse thing MDs have to do than a peer to peer for drug approval. Endless time wasted

Nirav Shah

Latest posts 5